Concord Biotech Key Ratios
NSE: CONCORDBIO | BSE: 543960
₹1,446.10
As on 31-Aug-2026IST
Market cap
₹15,167 Cr
Revenue (TTM)
₹1,108 Cr
P/E Ratio
55.1
P/B Ratio
7.3
Div. Yield
0.5 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -21.04 | 26.23 | -6.72 | 8.53 | 11.32 |
| EBIT | -35.07 | 47.35 | -26.64 | 1.79 | -0.47 |
| Net Profit | -34.08 | 32.84 | -21.99 | 4.23 | 1.99 |
| EPS | -34.08 | 32.84 | -22.67 | 3.93 | 2.13 |
| Book Value | -- | -- | 11.27 | 16.07 | 15.08 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 34.54 | 33.74 | 28.29 | 27.82 | 37.70 |
| Net Margin
| 27.58 | 26.68 | 23.29 | 23.41 | 29.86 |
| Return on equity
| 19.24 | 18.88 | 14.45 | 13.54 | 22.26 |
| Return on Capital
| 25.66 | 25.03 | -- | 18.04 | 29.62 |
| Return on Assets
| 17.09 | 15.91 | 12.66 | 12.15 | 19.90 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.00 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
18.04
|
29.62
|
29.13
|
26.70
|
|
Peer Median
|
--
|
15.48
|
16.46
|
15.49
|
--
|
ROE
14.45
Higher than Peers by 4.51
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
14.45
|
13.54
|
22.26
|
21.88
|
20.06
|
|
Peer Median
|
9.94
|
12.68
|
13.87
|
14.72
|
--
|
ROA
12.66
Higher than Peers by 5.40
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
12.66
|
12.15
|
19.90
|
19.17
|
15.92
|
|
Peer Median
|
7.26
|
7.69
|
8.04
|
7.19
|
--
|
EBIT Margin
28.29
Higher than Peers by 18.75
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
28.29
|
27.82
|
37.70
|
37.23
|
34.52
|
|
Peer Median
|
9.55
|
15.68
|
10.05
|
10.28
|
--
|
Net Margin
23.29
Higher than Peers by 14.66
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
23.29
|
23.41
|
29.86
|
29.32
|
27.02
|
|
Peer Median
|
8.64
|
11.16
|
9.11
|
6.78
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
31.63
|
35.50
|
35.57
|
34.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-6.72
Lower than Peers by 12.96
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
-6.72
|
-12.10
|
18.01
|
19.20
|
19.67
|
|
Peer Median
|
6.24
|
15.05
|
7.17
|
10.56
|
--
|
EBIT Growth
-26.64
Lower than Peers by 26.58
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
-26.64
|
-35.14
|
19.51
|
28.54
|
31.57
|
|
Peer Median
|
-0.06
|
19.88
|
12.05
|
6.17
|
--
|
Net Profit Growth
-21.99
Lower than Peers by 29.57
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
-21.99
|
-30.25
|
20.62
|
28.33
|
37.25
|
|
Peer Median
|
7.58
|
19.11
|
22.15
|
27.97
|
--
|
EPS Growth
-22.67
Lower than Peers by 24.85
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
-22.67
|
-29.80
|
20.62
|
28.33
|
37.25
|
|
Peer Median
|
2.18
|
23.11
|
8.80
|
--
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
11.27
|
18.74
|
18.34
|
16.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
--
|
0.00
|
0.00
|
0.02
|
|
Peer Median
|
0.02
|
0.12
|
0.03
|
0.05
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
--
|
0.00
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
7.39
Higher than Peers by 4.95
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
7.39
|
7.39
|
6.17
|
6.30
|
3.79
|
|
Peer Median
|
2.45
|
2.48
|
2.20
|
1.93
|
--
|
Quick Ratio
5.46
Higher than Peers by 3.75
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
5.46
|
5.46
|
4.87
|
4.84
|
2.69
|
|
Peer Median
|
1.72
|
1.82
|
1.72
|
1.59
|
--
|
Interest Coverage
1,386.30
Higher than Peers by 1,376.59
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
1,386.30
|
419.57
|
475.76
|
130.57
|
33.85
|
|
Peer Median
|
9.71
|
13.67
|
12.28
|
12.45
|
--
|
Operating Efficiency
Debtors to sales
41.52
Higher than Peers by 14.61
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
41.52
|
43.63
|
43.47
|
34.38
|
32.09
|
|
Peer Median
|
26.91
|
30.65
|
26.23
|
23.97
|
--
|
Asset Turnover
0.52
Lower than Peers by 0.15
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
0.52
|
0.49
|
0.64
|
0.63
|
0.57
|
|
Peer Median
|
0.67
|
0.70
|
0.74
|
0.88
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
169.86
|
132.49
|
111.87
|
108.22
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
97.92
|
68.07
|
75.42
|
87.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
159.68
|
123.94
|
149.88
|
179.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
108.11
|
76.63
|
37.41
|
16.22
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
55.08
Higher than Peers by 0.01
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
55.08
|
40.73
|
47.19
|
51.68
|
--
|
|
Peer Median
|
55.07
|
55.07
|
39.17
|
40.74
|
--
|
Price / Book Value
7.31
Higher than Peers by 2.83
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
7.31
|
5.27
|
9.67
|
10.43
|
--
|
|
Peer Median
|
4.48
|
4.76
|
3.61
|
3.87
|
--
|
Dividend Yield
0.52
Higher than Peers by 0.37
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
0.52
|
0.74
|
0.64
|
0.57
|
--
|
|
Peer Median
|
0.15
|
0.15
|
0.19
|
0.20
|
--
|
EV/EBITDA
34.45
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
34.45
|
25.25
|
31.81
|
34.08
|
0.00
|
|
Peer Median
|
--
|
39.78
|
28.79
|
25.41
|
--
|
Market Cap
15,167
Higher than Peers by 9,347
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
15,167
|
10,628
|
17,537
|
15,922
|
--
|
|
Peer Median
|
5,820
|
5,820
|
3,944
|
2,959
|
--
|